retatrutide clinical trial dose escalation Dosing Schedule: From Trials to Real Weight Loss Outcomes retatrutide clinical trial dose escalation

Three trials of short-acting GLP-1 receptor agonists showed slowed motor decline in Parkinson's disease, though the dedicated EVOKE trial of semaglutide for early Alzheimer's disease did not demonstrate significant benefit

In the SURMOUNT-5 trial, participants without diabetes taking the 15mg dose lost an average of 20.2% of their body weight over 72 weeks

When it occurs, it typically results from improved glucose control, increased fluid intake, or co-prescribed medications such as SGLT2 inhibitors or diuretics rather than the GLP-1 medication itself

Resources Regeneron COURAGE Trial interim results

Thanks for this great review showing the need to move the paradigm away from just small solute clearance as a measure of PD prescribing